| INTRODUC TI ON
Congenital heart disease (CHD) is the most common birth defect with various incidence of 4-50 per 1000 live births, worldwide, 1 consisting different types of cardiac malformations from severe forms such as tetralogy of Fallot (TOF) and transposition of the great arteries (TGA) to mild forms such as bicuspid aortic valve (BAV). 2 Although 8% of CHD cases are estimated to result from chromosomal abnormalities and single gene disorders 3 , the exact etiology of CHD is mostly unknown (about 75% of cases). 4 Previous studies indicated some transcription factors which play significant role in heart development including GATA binding protein 4 (GATA4), NOTCH, myosin heavy chain 6 (MYH6), NK2 homeobox 5 (NKX2-5), Zic family member 3 (ZIC3), T-box 5 (TBX5), and T-box 20 (TBX20). [5] [6] [7] Among these transcription factors, GATA4, located on 8p23.1, is expressed in endocardial, myocardial, and mesenchymal cells for suitable cardiac septation. 8 As a critical zinc finger transcription factor, it is important in different types of CHD causality, that is, TOF, ventricular septal defect (VSD), atrioventricular septal defect (AVSD), atrial septal defect (ASD), patent ductus arteriosus (PDA), and pulmonary valve stenosis (PS). 5, 6, 9, 10 Functional experiments in different animal models such as mice, fly, and fish demonstrated that any change in GATA4 sequence can affect cardiac development. 11, 12 Full length of GATA4 cDNA is 3371 bp, and it contains 6 exons. The GATA4 protein has 442 amino acids and binds to the GATA motif of target genes involved in cardiogenesis. 13 To date, based on Human Gene Mutation Database (HGMD) (www.hgmd.cf.ac.uk), 114 mutations in GATA4 gene have been reported in the CHD cases.
Given there are few studies [14] [15] [16] which surveyed CHD etiology in Iranian population, we evaluated the entire coding sequence of GATA4 gene in sixty-six familial CHD patients. This study is the first report of a clinical significance of a pathogenic GATA4 mutation in an
Iranian patient with BAV. Also, this study is the first report of a novel balanced translocation 5, 7 that may or may not related with heart defect phenotype in the same patient. 
| MATERIAL S AND ME THODS

| Study subjects and samples
| Primers, PCR, and direct Sanger sequencing
Five millilitre peripheral blood from each subject was collected in EDTA-containing tubes, and genomic DNA was extracted according to our in-house method based on the standard salting-out technique.
To amplify the entire GATA4 coding sequence as well as exon-intron boundaries, six primer pairs were designed (Table S1) 
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The generated sequences were aligned with the human refer- 
| Bioinformatics
Candidate variants were evaluated for their potential effect(s) on protein function and structure of GATA4 using bioinformatic prediction tools such as Mutation Taster (http://www.mutat ionta ster.
org/), 24 sorting intolerant from tolerant (SIFT) (http://sift.bii.a-star.
edu.sg/), 25 combined annotation-dependent depletion (CADD)
(http://cadd.gs.washi ngton.edu/home), 26 and polymorphism phenotyping v2 (PolyPhen-2) (http://genet ics.bwh.harva rd.edu/pph2/). 27 We also used CLUSTALW (https ://www.genome.jp/tools-bin/ clustalw) 28 for multiple alignment of GATA4 protein sequence in human as compared with other organisms. The potentially pathogenic variants were then traced inside the pedigree using PCR-based Sanger sequencing.
| RE SULT
| Cytogenetic analysis
Cytogenetic analysis of the patients for genome and chromosomal mutations appeared normal in all, but one, the CHD-7, for whom G-banding revealed a novel balanced translocation between chromosomes 5 and 7 (46,XY,t(5;7)(qter13;qter11)) in 20 metaphase spreads that were studied. Segregation analysis showed the absence of that translocation in both parents. To investigate the presence of any other pathogenic genomic mutation linked to CHD, WES was performed on the CHD-7 patient. Subsequently, a heterozygous c.1309G>A (p.Gly437Arg) variation in GATA4 coding sequence was identified. This case is further described below.
| De novo balanced 46,XY,t(5;7)(qter13;qter11) translocation does not seem to be causative for CHD
A 14-year-old boy to whom we are referring as CHD-7 throughout the study was admitted to our hospital suffering from shortness of breath. Clinical examination and echocardiography unraveled the presence of BAV, as shown in Figure 1A . Through genetic counseling, the history of CHD was confirmed in the pedigree. Proband's mother (III-8 in Figure 1B) , a 40-year-old lady, had been diagnosed with ASD at the age of 28. Her 62-year-old mother (II-4 in Figure 1B) was also suffering from the shortness of breath, started when she was 50 years old. However, she did not agree to participate in this study.
As stated before, 46,XY,t(5;7)(qter13;qter11) balanced translocation identified in the pedigree's proband (CHD-7 patient) was neither found in his affected mother nor in his healthy father ( Figure 1A ).
However, the heterozygous c.1309G>A (p.Gly437Arg) variation (rs748737164) identified in the proband (CHD-7 patient) by WES was detected in his affected mother (III-8 in Figure 1B) , as expected.
None of the other family members who were studied including II-3, III-7, and IV-3 individuals ( pulmonary stenosis (PS) (7.6%), TGA (7.6%), double outlet right ventricle (DORV) (4.5%), AVSD (3%), coarctation of the aorta (COA) (1.5%), hypoplastic left heart syndrome (HLHS) (1.5%), and BAV (1.5%). The outcome of GATA4 variant screening is summarized in Table 1 , and CHD types in our studied population are indicated in Table S2 . 
| D ISCUSS I ON
Sixty six CHD patients of various ethnicities within the Iranian population were screened in this study. Since our center is one the major country's referral hospitals for cardiogenetic diseases, the studied patients were of diverse ethnicities including Fars, Azeri, Kurd, Lur, Gilaki, Mazandarani, Arab, Turkmen, and Baloch. The presence of the disease in the patient was confirmed by expert cardiologists.
G-banding screening of all the patients resulted in identification of a de novo balanced chromosomal translocation, t(5;7) (qter13;qter11), in a 14-year-old boy with BAV. None of his parents including the mother who is suffering from ASD carry the translocation. Using WES data for CHD-7, we tried to identify chromosomal breakpoint locations but we failed. 30 In addition, no CHD-related CNV was identified throughout the chromosomes 5 and 7, as far as our WES data could have provide. Through WES of the mentioned patient (CHD-7), a heterozygous c.1309G>A (p.Gly437Arg) variation in GATA4 (one of the important CHD-associated genes) was identified to which no defined phenotype has been correlated. To the best of our knowledge, 16, 32, 33 the GATA4 gene can be considered as one of common genes involved in CHD etiology. We screened the entire coding sequence regions of the GATA4 gene among sixty-six CHD patients. Except for one, other pathogenic variant, the c.1220C>A observed in one family (2 cases), the rest were benign genetic polymorphisms that have been reported in some other populations, too.
GATA4 as a conserved transcription factor regulates over 30
genes that are signaling pathway players of the heart development. 34 GATA4 has two transcriptional activation domains (TAD), N-terminal zinc finger (NZF) and C-terminal zinc finger (CZF). 35 Locations of the two detected missense mutations, the p.Gly437Arg and p.Pro407Gln, in the protein structure are illustrated in Figure 3 .
The c.1309G>A mutation changes glycine to arginine residue at 437 position. In silico analyses confirmed that the altered amino acid in protein sequence was highly conserved among different species (Figure 3 ), and this mutation was predicted to be damaging.
To our knowledge, this study is the first report on the c.1309G>A c.1138G>A in their studied patient/control groups that has no effect in the CHD pathology. c.1129A>G was also reported previously in normal controls as well as CHD patients in some documents. 29, 39, 40 Variable expressivity has been reported in GATA4-causing
CHDs. 41 In a study by Tomita-Mitchell et al, 9 carriers of c.278G>C, In conclusion, here we report for the first time a de novo balanced translocation may or may not related to the CHD phenotype. We also present c.1309G>A as the BAV causing likely pathogenic mutation in GATA4 gene. As mentioned before, no clinical evidence for that mutation has been presented so far. Correlating GATA4 mutations to phenotypes in congenital BAV, ASD, and VSD provides a ground for early diagnosis of these defects in families who have affected individuals.
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